8-K: Propanc Biopharma Secures $1M in Series C Preferred Stock Private Placement

Propanc Biopharma, Inc. completed a private placement with Hexstone Capital LLC, raising $1,000,099 through the sale of Series C Preferred Stock and a Warrant.

Summary

• Closed a private placement with Hexstone Capital LLC, as previously disclosed in an 8-K filed on October 14, 2025.
• Hexstone Capital LLC purchased 100 shares of Series C Preferred Stock and a Warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock.
• The cash payment received by the company for this transaction was $1,000,099.00.
• The Series C Preferred Stock has a par value of $0.01 per share and a Stated Value of $10,000 per share.
• Each Series C Preferred Share is convertible into common stock at the holder's option, with a conversion price that is the lesser of a fixed $5.00 or 85% (or 70% if delisted) of the lowest trading price during a measurement period, subject to a floor price of $0.50.
• Dividends on the Preferred Shares are cumulative, accrue daily at 0% per annum, but automatically increase to 10% per annum upon a 'Triggering Event'.
• The Series C Preferred Stock ranks pari passu with the company's Series A and Series B Convertible Preferred Stock and senior to all other capital stock (Junior Stock) with respect to dividends, distributions, and liquidation payments.
• Holders of Series C Preferred Shares have voting rights on an as-converted basis, subject to a 4.99% beneficial ownership limitation, which can be increased up to 9.99% with 61 days' notice.
• The company cannot issue common stock upon conversion exceeding 19.9% of total outstanding common stock on the Initial Issuance Date without shareholder approval (Exchange Limitation).
• A comprehensive list of 'Triggering Events' (e.g., conversion failures, failure to pay dividends, bankruptcy, material adverse effect over $5,000,000, failure to maintain an effective registration statement for 40 days) can lead to mandatory redemption at a premium (110% of Conversion Amount).
• The company has the option to redeem all or any portion of the Preferred Shares at a price equal to 110% of the Stated Value plus any Additional Amount.
• Covenants restrict the company from redeeming or paying cash dividends on other capital stock (except as required by Series C terms), transferring material assets outside the ordinary course of business, changing its business nature, or issuing other dilutive securities without the consent of the Required Holders (majority of Series C holders).
• Dispute resolution for pricing and conversion calculations involves an independent investment bank, with fees and expenses borne solely by the company.

Sentiment

Score: 4

Explanation: While the company successfully raised capital, the terms of the Series C Preferred Stock are highly protective of the preferred holders and potentially very dilutive to common shareholders, especially given the floating conversion price and numerous triggering events that could force costly redemptions or further dilution. This structure suggests a company in need of capital that had to offer very favorable terms to secure funding.

Positives

• Successfully raised $1,000,099 in cash through a private placement, providing immediate capital for operations.
• The Series C Preferred Stock ranks senior to common stock and pari passu with other preferred series in liquidation, offering some security to preferred holders.
• The conversion mechanism allows holders to benefit from potential future common stock price appreciation, with downside protection via a floor price and discounted conversion rate.

Negatives

• The conversion terms, specifically the floating conversion price (lower of fixed price or 85% of lowest trading price), are highly dilutive to existing common shareholders if the stock price declines.
• The 10% dividend rate upon a 'Triggering Event' could become a significant financial burden if the company faces operational or compliance issues.
• The extensive list of 'Triggering Events' and associated redemption rights (at a 110% premium) grant significant control and leverage to the Series C Preferred Stock holders, potentially forcing the company into unfavorable actions or further dilution.
• The 19.9% Exchange Limitation without shareholder approval could hinder future conversions if the company's stock price drops significantly, requiring a shareholder vote for further dilution.
• The company is responsible for the fees and expenses of an independent investment bank for dispute resolution, adding potential costs.

Risks

• Dilution Risk: The conversion terms of the Series C Preferred Stock, particularly the floating conversion price (85% of the lowest trading price), pose a significant risk of substantial dilution to existing common stockholders if the common stock price declines.
• Financial Burden from Triggering Events: A wide range of 'Triggering Events' can lead to an increased dividend rate (10% per annum) and mandatory redemption at a premium (110% of Conversion Amount), which could severely strain the company's finances.
• Shareholder Approval for Further Dilution: The 19.9% Exchange Limitation means that if conversions exceed this threshold, the company will need shareholder approval, which could be difficult to obtain and delay necessary capital actions.
• Operational and Compliance Risks: Failure to cure conversion failures, maintain sufficient authorized shares, pay dividends, remove restrictive legends, or any material breach of transaction documents can trigger adverse redemption rights.
• Liquidity Risk: In a 'Bankruptcy Triggering Event,' the company is required to immediately redeem outstanding Preferred Shares in cash at a premium, potentially exacerbating financial distress.
• Control and Governance Impact: The 'Required Holders' (majority of Series C holders) have significant negative control rights, including consent for issuing senior preferred stock, certain asset transfers, changes in business, and amendments to the Certificate of Designations.
• Litigation Risk: The detailed dispute resolution mechanism and remedies for breaches, including specific performance and injunctive relief, indicate potential for legal disputes if terms are not met.

Future Outlook

The filing details the terms of a newly issued Series C Convertible Preferred Stock, which provides a mechanism for future equity conversions and potential capital raises through the warrant. The company's ability to manage its financial health and common stock price will significantly influence the dilutive impact of these conversions and the cost of potential redemptions.

Management Comments

• James Nathanielsz, Chief Executive Officer, certified the adoption of the resolution creating the Series C Convertible Preferred Stock.

Industry Context

This private placement is a common method for smaller biopharma companies to raise capital, especially when traditional equity markets might be less favorable or to secure funding from strategic investors. The complex terms of the preferred stock, including conversion discounts and redemption premiums, reflect the typical risk-reward profile sought by investors in early-stage or growth-oriented companies in the sector, often at the expense of common shareholder dilution.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Potential for significant dilution due to the conversion terms of the Series C Preferred Stock, especially if the common stock price declines. Their voting power could also be diluted as preferred shares convert.
• Series C Preferred Stock Holders (Hexstone Capital LLC): Gain significant protective rights, including senior ranking, cumulative dividends, anti-dilution provisions, and redemption rights at a premium upon various triggering events, providing a strong position in the capital structure.
• Company (Propanc Biopharma, Inc.): Receives immediate capital infusion of $1,000,099.00 but takes on substantial obligations and restrictions, including potential for high-cost redemptions and limitations on future corporate actions, which could impact operational flexibility.

Next Steps

• The company will need to manage its common stock price to mitigate the dilutive impact of future conversions of the Series C Preferred Stock.
• The company must ensure compliance with all covenants and avoid 'Triggering Events' to prevent increased dividend rates and mandatory redemptions at a premium.
• If conversions exceed 19.9% of outstanding common stock, the company will need to seek shareholder approval.

Key Dates

Recommendation

While the capital raise provides immediate funding, the terms of the Series C Preferred Stock are highly unfavorable for existing common shareholders. The floating conversion price (lower of fixed price or 85% of the lowest trading price, subject to a floor) creates a significant risk of severe dilution, especially if the common stock price continues to decline. The extensive list of 'Triggering Events' and associated mandatory redemption premiums (110%) or increased dividend rates (10%) place substantial financial burdens and control in the hands of the preferred holder, potentially forcing the company into further dilutive actions or financial distress. This structure suggests a distressed financing, making the common stock highly speculative and vulnerable to significant downside.

Keywords

Propanc Biopharma, PPCB, Series C Preferred Stock, Private Placement, Convertible Preferred Stock, Equity Financing, Dilution, SEC Filing, 8-K, Hexstone Capital, Corporate Governance, Capital Raise, Preferred Stock Terms, Biopharma